Genocea Biosciences Company Profile (NASDAQ:GNCA)

About Genocea Biosciences

Genocea Biosciences logoGenocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company's pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GNCA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.60
  • 50 Day Moving Average: $4.41
  • 200 Day Moving Average: $4.53
  • 52-Week Range: $3.28 - $8.07
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.44
  • P/E Growth: 0.00
  • Market Cap: $130.55M
  • Outstanding Shares: 28,380,000
  • Beta: 2.33
Profitability:
  • Return on Equity: -57.92%
  • Return on Assets: -44.92%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 10.79%
  • Quick Ratio: 10.79%
Additional Links:
Companies Related to Genocea Biosciences:

Analyst Ratings

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $19.40 (309.28% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Needham & Company LLCDowngradeBuy -> HoldView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformView Rating Details
12/14/2016Cowen and CompanySet Price TargetBuy$40.00View Rating Details
9/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$9.00 -> $12.00View Rating Details
4/1/2016Stifel NicolausBoost Price TargetBuy$11.00 -> $13.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Genocea Biosciences (NASDAQ:GNCA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)ViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)ViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)ViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)ViewListenView Earnings Details
2/12/2015Q414($0.55)($0.66)ViewListenView Earnings Details
11/6/2014Q314($0.51)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.52)($0.76)$0.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
Current Year EPS Consensus Estimate: $-1.88 EPS
Next Year EPS Consensus Estimate: $-1.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Genocea Biosciences (NASDAQ:GNCA)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 54.62%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
DateHeadline
News IconAnalyst Downgrades - Genocea Biosciences (NASDAQ:GNCA) Stock Gets Downgraded By Needham & Company (NASDAQ:GNCA)
prensariotiretail.com - February 19 at 4:54 PM
News IconGenocea Biosciences Inc (GNCA) Receives An Update From Brokers (NASDAQ:GNCA)
mundoaguaysaneamiento.net - February 19 at 4:54 PM
News IconGenocea Biosciences Inc GNCA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:GNCA)
www.bioportfolio.com - February 18 at 12:23 PM
biz.yahoo.com logoGENOCEA BIOSCIENCES, INC. Files SEC form 10-K, Annual Report (NASDAQ:GNCA)
biz.yahoo.com - February 18 at 12:23 PM
marketexclusive.com logoAnalyst Downgrades – Genocea Biosciences (NASDAQ:GNCA) Stock Gets Downgraded By Needham & Company LLC from Buy to Hold (NASDAQ:GNCA)
marketexclusive.com - February 17 at 4:04 PM
finance.yahoo.com logoGenocea Biosciences downgraded by Needham (NASDAQ:GNCA)
finance.yahoo.com - February 17 at 4:04 PM
4-traders.com logoGENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Results of Operations and Financial Condition (NASDAQ:GNCA)
www.4-traders.com - February 16 at 5:24 PM
biz.yahoo.com logoQ4 2016 Genocea Biosciences Inc Earnings Release - Time Not Supplied (NASDAQ:GNCA)
us.rd.yahoo.com - February 16 at 5:24 PM
us.rd.yahoo.com logoGenocea Reports Fourth Quarter and Year-End 2016 Financial Results (NASDAQ:GNCA)
us.rd.yahoo.com - February 16 at 5:24 PM
biz.yahoo.com logoGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:GNCA)
us.rd.yahoo.com - February 16 at 5:24 PM
sg.finance.yahoo.com logoGenocea Biosciences reports 4Q loss (NASDAQ:GNCA)
sg.finance.yahoo.com - February 16 at 5:24 PM
News IconInsiders Are Buying Genocea Biosciences, Inc. (NASDAQ:GNCA) - Winfield Review (NASDAQ:GNCA)
winfieldreview.com - February 13 at 6:25 PM
finance.yahoo.com logoGenocea to Host Fourth Quarter and Year End 2016 Financial Results Conference Call & Webcast on February 16, 2017 (NASDAQ:GNCA)
finance.yahoo.com - February 9 at 6:16 PM
nasdaq.com logoShould You Sell Genocea Biosciences (GNCA) Before Earnings? - Nasdaq (NASDAQ:GNCA)
www.nasdaq.com - February 8 at 11:06 PM
finance.yahoo.com logoShould You Sell Genocea Biosciences (GNCA) Before Earnings? (NASDAQ:GNCA)
finance.yahoo.com - February 7 at 6:45 PM
investornewswire.com logoGenocea Biosciences, Inc. (NASDAQ:GNCA) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:GNCA)
www.investornewswire.com - February 5 at 10:18 PM
News IconGenocea Biosciences, Inc. (NASDAQ:GNCA) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - February 5 at 10:18 PM
News IconQuarterly EPS Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Set At $-0.71 - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - February 3 at 10:58 PM
News IconTrading Radar: Checking Technicals for Genocea Biosciences Inc. (GNCA) - Sherwood Daily (NASDAQ:GNCA)
sherwooddaily.com - February 2 at 11:07 PM
News IconInvestor Focus on Technical Levels for Genocea Biosciences Inc. (GNCA) - Sherwood Daily (NASDAQ:GNCA)
sherwooddaily.com - January 30 at 6:09 PM
News IconAre Insiders Bumping Up Their Positions in Genocea Biosciences, Inc. (NASDAQ:GNCA) - Wall Street Beacon (NASDAQ:GNCA)
wsbeacon.com - January 30 at 6:09 PM
News IconStock Perspective: Genocea Biosciences, Inc. (NASDAQ:GNCA) Company Earnings Watch - Aiken Advocate (NASDAQ:GNCA)
aikenadvocate.com - January 29 at 3:41 AM
News IconChart Indicators in Focus for Genocea Biosciences Inc. (GNCA) - Rives Journal (NASDAQ:GNCA)
rivesjournal.com - January 29 at 3:41 AM
News IconGenocea Biosciences, Inc. (NASDAQ:GNCA) Bearish Target At $40 ... - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - January 26 at 6:57 PM
News IconEarnings in Full Force, Analysts Take Aim at Genocea Biosciences ... - Wall Street Beacon (NASDAQ:GNCA)
wsbeacon.com - January 26 at 6:57 PM
News IconChecking the Piotroski Score on Shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) - The Tribune (NASDAQ:GNCA)
lakecitytribune.com - January 24 at 6:11 PM
News IconTechnical Toolbox: Investor Focus on Genocea Biosciences Inc. (GNCA) - Sherwood Daily (NASDAQ:GNCA)
sherwooddaily.com - January 24 at 6:11 PM
News IconStock Tracker: Earnings & Estimates for Genocea Biosciences, Inc. (NASDAQ:GNCA) - Aiken Advocate (NASDAQ:GNCA)
aikenadvocate.com - January 21 at 10:25 PM
News IconGrowth Story Unfolding for Genocea Biosciences, Inc. (NASDAQ:GNCA) - Prospect Journal (NASDAQ:GNCA)
prospectjournal.com - January 17 at 3:28 PM
News IconTracking Corporate Insiders: What Are They Doing With Genocea Biosciences, Inc. (NASDAQ:GNCA) - Wall Street Beacon (NASDAQ:GNCA)
wsbeacon.com - January 17 at 3:28 PM
News IconGenocea Biosciences, Inc. (NASDAQ:GNCA) Quarterly EPS Set At $-0.71 - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - January 15 at 10:12 PM
News IconGenocea Biosciences Inc GNCA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:GNCA)
www.bioportfolio.com - January 13 at 6:35 PM
News IconWill The Needle Move For Genocea Biosciences, Inc. (NASDAQ:GNCA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:GNCA)
wsbeacon.com - January 13 at 8:20 AM
News IconGenocea Biosciences Inc (NASDAQ:GNCA) Is A Discount Opportunity - Insider Financial (NASDAQ:GNCA)
www.insiderfinancial.com - January 13 at 8:20 AM
News IconReady for an Upsurge? Analysts Chime in on Genocea Biosciences, Inc. (NASDAQ:GNCA) - Prospect Journal (NASDAQ:GNCA)
prospectjournal.com - January 9 at 9:18 PM
capitalcube.com logoETFs with exposure to Genocea Biosciences, Inc. : January 9, 2017 (NASDAQ:GNCA)
www.capitalcube.com - January 9 at 4:17 PM
News IconGenocea Biosciences Inc (GNCA) Broker Price Targets For The Coming Week (NASDAQ:GNCA)
prensariotiretail.com - January 8 at 10:14 PM
News IconGenocea Biosciences Inc. (GNCA) Issues Quarterly Earnings Results (NASDAQ:GNCA)
perspectivabetica.com - January 8 at 10:14 PM
News IconDaily Sentiment Score Of Genocea Biosciences, Inc. (NASDAQ ... - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - January 8 at 5:14 PM
nasdaq.com logoGenocea Reports Positive 6-Month Results From GEN-003 Phase 2b Trial (NASDAQ:GNCA)
www.nasdaq.com - January 5 at 6:25 PM
streetinsider.com logoGenocea Biosciences (GNCA) Announces Positive Interim Analysis of GEN-003 Phase 2b Clinical Trial (NASDAQ:GNCA)
www.streetinsider.com - January 5 at 6:25 PM
schaeffersresearch.com logoBuzz Stocks: Sears Holdings Corp, Halozyme Therapeutics, Inc., and Genocea Biosciences Inc (NASDAQ:GNCA)
www.schaeffersresearch.com - January 5 at 6:25 PM
us.rd.yahoo.com logoGenocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial (NASDAQ:GNCA)
us.rd.yahoo.com - January 5 at 6:25 PM
biz.yahoo.com logoGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:GNCA)
us.rd.yahoo.com - January 5 at 6:25 PM
finance.yahoo.com logoWhy These 5 Biopharma Stocks Are Making Massive Gains on Thursday (NASDAQ:GNCA)
finance.yahoo.com - January 5 at 6:25 PM
News IconStock Momentum in Focus on Shares of Genocea Biosciences Inc. (GNCA) - Yankee Analysts (NASDAQ:GNCA)
yankeeanalysts.com - December 20 at 10:24 PM
4-traders.com logoGenocea Biosciences : Announces Research Collaboration with Checkmate Pharmaceuticals in Advanced Melanoma (NASDAQ:GNCA)
www.4-traders.com - December 15 at 6:02 PM
smarteranalyst.com logoNeedham Likes Genocea Biosciences Inc (GNCA) Potential for Upside Following R&D Day; Shares Rise 8% (NASDAQ:GNCA)
www.smarteranalyst.com - December 15 at 6:02 PM
News IconGenocea Biosciences, Inc. (NASDAQ:GNCA) Bearish Target At $40 - Stock Observer (NASDAQ:GNCA)
www.thestockobserver.com - December 14 at 11:11 PM
streetinsider.com logoGenocea Biosciences (GNCA) Enters Collaboration with Checkmate ... - StreetInsider.com (NASDAQ:GNCA)
www.streetinsider.com - December 14 at 11:11 PM

Social

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?

5 analysts have issued 1 year target prices for Genocea Biosciences' stock. Their forecasts range from $12.00 to $40.00. On average, they expect Genocea Biosciences' share price to reach $19.40 in the next year.

When will Genocea Biosciences announce their earnings?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:

  • Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)
  • According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (1/5/2017)

Who owns Genocea Biosciences stock?

Genocea Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Franklin Resources Inc. (10.55%), Deerfield Management Co. (2.42%), Alyeska Investment Group L.P. (0.79%), Dimensional Fund Advisors LP (0.18%) and Birchview Capital LP (0.14%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jessica Baker Flechtner, Jonathan Poole, Polaris Venture Management Co, Stephen J Hoffman and William D Clark.

Who sold Genocea Biosciences stock? Who is selling Genocea Biosciences stock?

Genocea Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc..

Who bought Genocea Biosciences stock? Who is buying Genocea Biosciences stock?

Genocea Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Alyeska Investment Group L.P.. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole, Stephen J Hoffman and William D Clark.

How do I buy Genocea Biosciences stock?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Genocea Biosciences stock cost?

One share of Genocea Biosciences stock can currently be purchased for approximately $4.74.

Genocea Biosciences (NASDAQ:GNCA) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Earnings History Chart

Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Dividend History Chart

Dividend Payments by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Last Updated on 2/22/2017 by MarketBeat.com Staff